Eur Rev Med Pharmacol Sci 2010; 14 (4): 356-362 Transarterial chemoembolization (TACE) for unresectable HCC: A new life begins? M. Biolato*, G. Marrone*, S. Racco*, C. Di Stasi**, L. Miele*, G. Gasbarrini*, R. Landolfi*, A. Grieco*
Eur Rev Med Pharmacol Sci 2010; 14 (4): 352-355 Epidemiology, risk factors and surveillance of hepatocellular carcinoma G. Cabibbo 1,2 A. Craxì 1
Eur Rev Med Pharmacol Sci 2010; 14 (4): 347-351 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues L. Bodei, G. Pepe, G. Paganelli
Eur Rev Med Pharmacol Sci 2010; 14 (4): 342-346 New biological agents for the treatment of the “high risk” IBD patients L. Guidi, M. Marzo, C. Felice, G. Mocci, L. Sparano, D. Pugliese, I. De Vitis, A. Papa, A. Armuzzi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 334-341 The role of multimodality treatment in M0 rectal cancer: evidence and research V. Valentini, M.C. Barba, M.A. Gambacorta
Eur Rev Med Pharmacol Sci 2010; 14 (4): 327-333 Surgical treatment of small bowel neoplasms C. Coco, G. Rizzo, A. Manno, C. Mattana, A. Verbo
Eur Rev Med Pharmacol Sci 2010; 14 (4): 320-326 Small bowel nonendocrine neoplasms: current concepts and novel perspectives A.C. Piscaglia, M. Campanale, G. Gasbarrini
Eur Rev Med Pharmacol Sci 2010; 14 (4): 315-319 Surgical issues after neoadjuvant treatment for gastric cancer D. D’Ugo, R. Persiani, M. Zoccali, F. Cananzi, V. Vigorita, P. Mazzeo, A. Tufo, A. Biondi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 309-314 Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives A. Bittoni, E. Maccaroni, M. Scartozzi, R. Berardi, S. Cascinu
Eur Rev Med Pharmacol Sci 2010; 14 (4): 302-308 Risk factors in gastric cancer D. Compare, A. Rocco, G. Nardone
Eur Rev Med Pharmacol Sci 2010; 14 (4): 292-301 Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia G. Mantovani
Eur Rev Med Pharmacol Sci 2010; 14 (4): 285-291 Chemoprophylaxis in gastrointestinal tumors M. Zilli, S. Iacobelli
Eur Rev Med Pharmacol Sci 2010; 14 (4): 272-276 Progress in endoscopic imaging of gastrointestinal tumors G. Costamagna, M. Marchese
Eur Rev Med Pharmacol Sci 2010; 14 (4): 269-271 General principles of chemotherapy E. Ricevuto, G. Bruera, P. Marchetti
Eur Rev Med Pharmacol Sci 2010; 14 (4): 263-268 Inflammation and cancer: a multifaceted link A. Sgambato, A. Cittadini
Eur Rev Med Pharmacol Sci 2010; 14 (4): 259-262 Gastrointestinal and liver tumours and public health in Europe T. Milosavljevic, M. Kostic-Milosavljevic, I. Jovanovic, M. Krstic
Eur Rev Med Pharmacol Sci 2010; 14 (4): 249-258 Epidemiology of gastrointestinal and liver tumors László Herszényi, Zsolt Tulassay
Eur Rev Med Pharmacol Sci 2010; 14 (3): 171-176 Gastroprotective effect of earthworm paste (Lampito mauritii, Kinberg) on experimental gastric ulcer in rats M. Prakash, G. Gunasekaran
Eur Rev Med Pharmacol Sci 2010; 14 (3): 163-170 The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial V. Ojetti, G. Gigante, M. Gabrielli, M.E. Ainora, A. Mannocci*, E.C. Lauritano, G. Gasbarrini, A. Gasbarrini
Eur Rev Med Pharmacol Sci 2010; 14 (3): 155-162 Octatropine methyl bromide and diazepam combination (Valpinax®) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial F. Pace‡, A. Maurano^, C. Ciacci**, V. Savarino†, A. Attili*, G. Iaquinto^^, E. Magni§, G. Bianchi Porro‡
